ReviewUrology annals
Efficacy and safety of solifenacin for overactive bladder: An updated systematic review and meta-analysis.
Review in Urology annals. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Overactive bladder (OAB) is a chronic disease with the symptoms of urgency with or without incontinence. Solifenacin is an antimuscarinic drug that Excels in OAB treatment due to its specific bladder receptor targeting. While previous research had positive outcomes, reports of adverse events (AEs) highlight the need for regular updates on the safety and efficacy of solifenacin for OAB management. This study followed PRISMA 2020 guidelines and was registered to PROSPERO CRD42023445318. A comprehensive search of PubMed, ScienceDirect, and Scopus databases was conducted until July 2023. Data were analyzed using Review Manager version 5.4 (The Cochrane Collaboration, The Nordic Cochrane Centre, Copenhagen, Denmark). Solifenacin had a significantly better effect in decreasing urgency episode (mean difference (MD) = -1.09, 95% confidence interval [CI]: -1.29--0.89,
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.